Oxford Immunotec Global PLC revised revenue guidance for the first quarter of 2020. Revenues for the first quarter were near the high end of its first quarter guidance range, which was $10.7 million to $14.1 million, in part due to successful shipment and importation of T-SPOT.TB kits into China.

Given the uncertainties around the scope and duration of the pandemic, and its continued impact on business, the company is withdrawing previously stated 2020 full year revenue guidance.